Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B02BD10 | Von Willebrand factor | B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| WILLFACT Powder and solvent for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Von Willebrand factor is an active ingredient of these brands:
United States (US)
Austria (AT)Brazil (BR)Croatia (HR)Ecuador (EC)
Estonia (EE)Finland (FI)France (FR)Ireland (IE)Lithuania (LT)Malta (MT)
Netherlands (NL)Poland (PL)Romania (RO)Spain (ES)Turkey (TR)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
